Business View Magazine | February 2020

142 BUSINESS VIEW MAGAZINE FEBRUARY 2020 AT A GLANCE CANNTAB THERAPEUTICS WHAT: A cannabis technology company WHERE: Cobourg, Ontario, Canada WEBSITE: C anntab Therapeutics is on a mission to provide doctors with a proper, accurate medical solution for prescribing cannabis. Currently, Canntab is the only company in North America to have developed a product line of solid oral dose formulations for a variety of cannabis cannabinoid (THC & CBD) and terpenoid blends in exacting dosages. With 13 patents pending in Canada and the United States, covering proprietary processes and solid oral dose formulations for extended release, immediate release, flash melt, and bi-layered medications, Canntab is showing a clear and sustainable competitive advantage. Additionally, Canntab has applied for its Cannabis Research Licence in Canada. The research licence will probably be acquired before Canntab obtains Licensed Producer status, which will allow the company to receive oil and begin preparing product submissions to Health Canada for full-scale manufacturing. Canntab trades on the Canadian Securities Exchange under the symbol PILL, on the OTCQB under the symbol CTABF, and on the Frankfurt Stock Exchange under the symbol TBF1. The company’s Markham, Ontario facility is designed and fully equipped to accommodate all manufacturing necessary to produce pharmaceutical grade cannabis hard pill formulations (solid oral dosage forms), which the firm believes is the future of medical cannabis. “After almost a year-and-a-half of consulting, designing, and building, we have reached an important milestone in Canntab’s business development: we have submitted our final evidence package to Health Canada for review,” explains Jeff Renwick, Co-Founder and CEO of Canntab. “With our license, we will be able to manufacture hundreds of thousands of hard pills a day in a growing variety of formulations that are unique in the marketplace.” Over the past 18 months, Canntab has been working on the development of tablets and different delivery systems at a Cobourg, Ontario facility owned by licensed producer, FSD Pharma, while building out their Markham facility in order to be a licensed producer non-grower. ON A MED I CAL MI S S I ON